San Diego, CA, USA – August 20, 2012 — HUYA Bioscience International announced today a strategic partnership with one of China’s leading research organizations, Tianjin Research Center of Basic Medical Sciences (TJRCBMS). HUYA is an international leader in accelerating the global development of China’s pharmaceutical innovations. Their new partnership with TJRCBMS will focus on innovations coming out of this newly formed institution that could meet critical global pharmaceutical pipeline needs.
Located on the Tianjin Medical University campus, TJRCBMS is a nonprofit research institution founded by the municipal government of Tianjin. Its mission is to be on the global biomedical research frontiers and serve China’s strategic development needs. Since its opening in 2005, it has recruited high-caliber principal investigators from China as well as from overseas to establish laboratories and conduct cutting-edge research in areas such as translational cancer biology, neural information processing, and gene therapy. Many of these investigators are well established in their respective research areas and have published extensively in peer-reviewed scientific journals.
The new partnership between HUYA and TJRCBMS will enable both parties to collaborate to promote new drug development in China and worldwide. TJRCBMS will be able to consult with HUYA’s team of experts in drug development and globalization. In turn, HUYA will have the first opportunity to evaluate certain research and development projects conducted at TJRCBMS, and provide support and assistance as needed.
“Working with Tianjin Research Center of Basic Medical Sciences puts us at the cutting edge of biomedical research in China,” said Clement Gingras, HUYA’s Chief Technical Officer and COO, China. “We are very excited about this opportunity and look forward to fruitful collaborations in the years to come.”
Professor Ning Zhang, the Director for TJRCBMS also expressed his optimism about this new partnership: “HUYA can provide their expertise on pharmaceutical development to help accelerate the global reach of our innovative research.”
China, the most comprehensive Chinese compound portfolio in the world, and a growing number of collaboration agreements with premier Chinese research and development organizations, HUYA occupies a unique position with regards to the China bio- pharmaceutical industry. Its strategy to identify and license novel Chinese compounds, and to offer Western pharmaceutical companies efficient and comprehensive access to therapeutic innovation in China, means the Company can enable efficient global development. HUYA has become a champion in guiding China’s biomedical innovations into the worldwide marketplace. HUYA is jointly headquartered in Shanghai and in San Diego, California. More information is available at www.huyabio.com.
About Tianjin Research Center of Basic Medical Sciences
With initial funding of 30 million RMB from the municipal government of Tianjin, Tianjin Research Center of Basic Medical Sciences was established as a non-profit research institution to advance the biomedical research and serve China’s strategic development needs. With its innovative open recruiting strategy and supportive management policies, TJRCBMS has attracted top talent globally to establish laboratories to conduct research in areas covering translational cancer biology, pharmaceutical sciences, neural information processing, epigenetics and tumorigenesis, molecular and populational genetics, gene therapy, molecular immunology as well as immunology and inflammation. For more information, please visit http://202.113.48.12/cn/expcenter/chinese.html.
Contact
Clement Gingras
CTO and COO, China
HUYA Bioscience International
+1.858.798.8800
cgingras@huyabio.com